B+
Bull case
20%
Probability
Target price
$8.50
Analysis reference price unavailable
Analysis 2026-07-31 · RankAlpha Sentiment Codex
ALGS
Aligos TherapeuticsDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$4.50
Analysis reference price unavailable
Analysis 2026-07-31 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$2.00
Analysis reference price unavailable
Analysis 2026-07-31 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-07-31
Recent news sentiment (30D)
+0.3
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+47.8
Score
AI commentary
Recent company news is positive because of the $25 million China-license payment and progress toward the next B-SUPREME interim analysis, but the payment-related relief appears largely priced in. The peer set is loose and useful mainly for clinical context, not valuation. No dependable analyst-revision, options, short-interest, employee, or social signal is available; confidence therefore remains limited despite strong primary-source coverage.
RankAlpha Sentiment Codex - 2026-07-31
Open full AI memoEvidence flagged
small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report
Impact
tentative
Confidence
-
AI events
2026-10-29eventSecond B-SUPREME interim analysisHigh impact
A second protocol-defined interim analysis for pevifoscorvir sodium is expected in the second half of 2026. The first interim analysis did not meet futility criteria and led to sample-size expansion, but Aligos remains blinded and efficacy remains incompletely disclosed [#PR-EARNINGS-2026-05-08] [#SEC-8K-2026-05-07].
2026-10-29catalystChina-license cash relief is largely priced inHigh impact
The Amoytop deal delivered a $25 million upfront payment, plus potential milestones and royalties, improving near-term financing flexibility. The payment was received on July 6 and the initial repricing appears substantially reflected in the stock [#SEC-8K-2026-04-16] [#PR-2026-07-06].
2027-07-31catalystPevifoscorvir clinical and Greater China optionalityHigh impact
The Phase 2 B-SUPREME program remains the principal value driver, with topline data planned for 2027; the Greater China license adds potential development, regulatory, commercial milestones, and royalties but remains dependent on clinical and regional execution [#PR-EARNINGS-2026-05-08] [#SEC-10Q-2026-05-07].
Recommendation
N/A
No formal recommendation provided.
As of 2026-07-31 • Updated nightlySource: Internal modelMethodology